CV benefits of dapagliflozin evident regardless of baseline kidney function

摘要

The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022. “[D]apagliflozin reduced the risk of the composite of CV death or worsening HF regardless of baseline kidney function,” said the authors. “[A] greater absolute risk reduction [was observed] in those with lower estimated glomerular filtration rate [eGFR],” they added.